Time-tested safety: FCARH143’s 5-year myeloma journey
S
Samer Al Hadidi
(1Myeloma, Waldenstrom’s, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX)
Article Details
Journal
Blood
Volume / Issue
Vol. 146, Issue 5
Published
July 31, 2025
Pages
519-520
ISSN
0006-4971
Publisher
Elsevier BV
Authors (1)
S
Samer Al Hadidi
1Myeloma, Waldenstrom’s, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX
Related Articles from this Journal
NOTCHing the MSC-endothelial interplay in the HSC niche
Simón Méndez-Ferrer
Aug 2026
10.1182/blood.2026034119
Procr+ endothelial progenitor cells govern hematopoiesis through fine-tuning mesenchymal stem cell niche signals
Chang Xu, Xue Lv et al.
Aug 2026
10.1182/blood.2025031474
Li C, Wu B, Li Y, et al. Loss of sphingosine kinase 2 promotes the expansion of hematopoietic stem cells by improving their metabolic fitness. <i>Blood</i> . 2022;140(15):1686-1701.
Aug 2026
10.1182/blood.2026035281
Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis
Karthik Chetlapalli, Satoko Ito et al.
Aug 2026
10.1182/blood.2025032290
Granulopoiesis under attack by mutant IDH1
Hideyo Hirai
Aug 2026
10.1182/blood.2026034486